Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;14(2):145-154.
doi: 10.1007/s12178-021-09695-7. Epub 2021 Jan 23.

The Use of Biologics for Hip Preservation

Affiliations
Review

The Use of Biologics for Hip Preservation

Toufic R Jildeh et al. Curr Rev Musculoskelet Med. 2021 Apr.

Abstract

Purpose of review: A wide array of nonoperative modalities to treat hip pain are aimed at restoring and maintaining the structural and physiologic characteristics of the joint. The purpose of this review is to describe the current understanding of biologics in hip pathology by providing an evidence-based overview of treatment modalities available for orthopedic surgeons.

Recent findings: The use of biologics as a primary treatment or adjunct to traditional management has shown encouraging results for the treatment of hip pain. Studies have demonstrated safety with minimal complications when using platelet rich plasma, hyaluronic acid, or stem cells to treat hip pain caused by osteoarthritis, femoroacetabular impingement syndrome, tendinopathy, or osteonecrosis of the femoral head. Several studies have been able to demonstrate meaningful clinical results that can improve treatment standards for hip pain; however, more work must be performed to better delineate the appropriate protocols, indications, and limitations of each modality. Recent advances have inspired renewed interest in biologics for patients with hip pain. We present a concise review of platelet rich plasma, hyaluronic acid, stem cells, and matrix metalloprotease inhibitors and their applicability to hip preservation surgery.

Keywords: Biologics; Hip; Hyaluronic acid; Platelet-rich plasma; Stem cells.

PubMed Disclaimer

Conflict of interest statement

Kelechi R. Okoroha reports potential conflicts of interest from the following companies: Arthrex (grand and education), Smith & Nephew (education, travel, lodging), Pinnacle (education), Medwest Associates (education), Wright Medical Technology (travel and lodging), Stryker Corporation (travel and lodging).

Toufic R. Jildeh, Muhammad J. Abbas, and Patrick Buckley declare that they have no conflict of interest.

Similar articles

Cited by

References

    1. Moss AS, Murphy LB, Helmick CG et al. Annual incidence rates of hip symptoms and three hip OA outcomes from a U.S. population-based cohort study: the Johnston County Osteoarthritis Project. Osteoarthr Cartil. 2016;24:9. - PMC - PubMed
    1. Poultsides LA, Asheesh Bedi BTK. An algorithmic approach to mechanical hip pain. HSS J. 2012;8:11. doi: 10.1007/s11420-012-9304-x. - DOI - PMC - PubMed
    1. Birnbaum K, Prescher A, Hessler S, et al. The sensory innervation of the hip joint--an anatomical study. Surg Radiol Anat. 1997;19:371–375. doi: 10.1007/BF01628504. - DOI - PubMed
    1. Adler KL, Cook PC, Yen Y-M, et al. Current concepts in hip preservation surgery: part I. Sports Health. 2015;7:8. doi: 10.1177/1941738115587270. - DOI - PMC - PubMed
    1. Griffin DR, Dickenson EJ, O'Donnell J et al. The Warwick Agreement on femoroacetabular impingement syndrome (FAI syndrome): an international consensus statement. Br J Sports Med. 2016;50:8. - PubMed